Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUCELL CORP /DE/ICCC · Entity 6837 | Director · VP of Sales and Marketing | April 16, 2025 | April 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUCELL CORP /DE/
Report date April 16, 2025 · Filed April 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.49 · Expires 2030-04-16 | Direct | 5,000 |
Reported balance
After 2025-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-16 · Grant · Acquired 5,000 · Balance 5,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2026 Filed Jan 29, 2026 16:42 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantStock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.27 | $0.00 |
DisclosureSEC source: 0001437749-26-002369 · rdgdoc.xml · derivative · entry 1 Brockmann Bobbi Jo · CIK 0001517536 · Director · VP of Sales and Marketing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-01-27 F1 · derivative.exercise_date: Option grant made to Ms. Brockmann in connection with her employment as Vice President of Sales and Marketing. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 33,333 shares becoming exercisable on each of January 27, 2027 and January 27, 2028 and 33,334 shares becoming exercisable on January 27, 2029. Read SEC document |
| April 16, 2025 Filed Apr 14, 2026 19:37 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantIncentive Stock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001437749-26-012234 · rdgdoc.xml · derivative · entry 1 Brockmann Bobbi Jo · CIK 0001517536 · Director · VP of Sales and Marketing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-04-16 Read SEC document |
| January 31, 2022 Filed Feb 9, 2022 21:59 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantIncentive Stock Options (Right to buy) · Derivative | 18,000 | $8.15 Strike: $8.15 | $146,700.00 |
DisclosureSEC source: 0001213900-22-006179 · doc4.xml · derivative · entry 1 Brockmann Bobbi Jo · CIK 0001517536 · Director · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2032-02-09 Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 15:21 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | Disposition to issuerIncentive Stock Options (Right to buy) · Derivative | 5,258 | $3.15 Strike: $3.15 | $16,562.70 |
DisclosureSEC source: 0001213900-20-042167 · doc4.xml · derivative · entry 2 Brockmann Bobbi Jo · CIK 0001517536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 5,258 shares Expires 2020-12-14 Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 15:21 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantCommon Stock, par value $0.10 per share | 4,742 | $3.15 | $14,937.30 |
DisclosureSEC source: 0001213900-20-042167 · doc4.xml · nonDerivative · entry 1 Brockmann Bobbi Jo · CIK 0001517536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,521 Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 21:14 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantIncentive Stock Options (Right to buy) · Derivative | 10,000 | $5.18 Strike: $5.18 | $51,750.00 |
DisclosureSEC source: 0001213900-19-025994 · doc4.xml · derivative · entry 4 Brockmann Bobbi Jo · CIK 0001517536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-12-11 Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 21:14 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | Disposition to issuerIncentive Stock Options (Right to buy) · Derivative | 3,476 | $3.65 Strike: $3.65 | $12,687.40 |
DisclosureSEC source: 0001213900-19-025994 · doc4.xml · derivative · entry 5 Brockmann Bobbi Jo · CIK 0001517536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,476 shares Expires 2020-01-04 Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 21:14 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | Disposition to issuerIncentive Stock Options (Right to buy) · Derivative | 3,800 | $3.99 Strike: $3.99 | $15,162.00 |
DisclosureSEC source: 0001213900-19-025994 · doc4.xml · derivative · entry 3 Brockmann Bobbi Jo · CIK 0001517536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,800 shares Expires 2020-02-08 Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 21:14 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantCommon Stock, par value $0.10 per share | 1,524 | $3.65 | $5,562.60 |
DisclosureSEC source: 0001213900-19-025994 · doc4.xml · nonDerivative · entry 2 Brockmann Bobbi Jo · CIK 0001517536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,779 Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 21:14 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantCommon Stock, par value $0.10 per share | 1,200 | $3.99 | $4,788.00 |
DisclosureSEC source: 0001213900-19-025994 · doc4.xml · nonDerivative · entry 1 Brockmann Bobbi Jo · CIK 0001517536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,255 Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 14:15 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantIncentive Stock Options (Right to buy) · Derivative | 7,500 | $7.80 Strike: $7.80 | $58,500.00 |
DisclosureSEC source: 0001213900-18-000337 · doc4.xml · derivative · entry 1 Brockmann Bobbi Jo · CIK 0001517536 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-01-08 Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:29 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantIncentive Stock Option (Right fo Buy) · Derivative | 10,000 | $5.84 Strike: $5.84 | $58,400.00 |
DisclosureSEC source: 0001547522-17-000016 · doc4.xml · derivative · entry 2 Brockmann Bobbi Jo · CIK 0001517536 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-09 Read SEC document |
| December 16, 2015 Filed Feb 14, 2017 17:29 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantIncentive Stock Option (Right to buy) · Derivative | 10,000 | $7.54 Strike: $7.54 | $75,400.00 |
DisclosureSEC source: 0001547522-17-000016 · doc4.xml · derivative · entry 1 Brockmann Bobbi Jo · CIK 0001517536 · VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2025-12-15 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.